26 -6 (38) 2021 — Kadirova Sh.A., Jumanazarov S.B., — CLINICAL FEATURES OF RENAL DAMAGE IN GOUT

CLINICAL FEATURES OF RENAL DAMAGE IN GOUT

Kadirova Sh.A., Tashkent Medical Academy Urgench branch of Tashkent Medical Academy

Jumanazarov S.B. Tashkent Medical Academy Urgench branch of Tashkent Medical Academy

Sapayeva Z.A. Tashkent Medical Academy Urgench branch of Tashkent Medical Academy

Resume

The literature data on the issues of kidney damage in patients with gout are presented, and special attention is paid to the relationship of purine metabolism with the characteristics of these disorders. The relationship between uric acid levels and renal function has been mentioned in the context of so-called gouty nephropathy – kidney damage caused by gout. The continuously increasing interest in this problem in recent years, the development of modern technologies and the growing number of serious studies devoted to gout and renal pathology, give hope for a progressive expansion of our knowledge and clinical capabilities.

Keywords: gout, hyperuricemia, gouty nephropathy

First page

145

Last page

149

For citation: Kadirova Sh.A., Jumanazarov S.B., Sapayeva Z.A. CLINICAL FEATURES OF RENAL DAMAGE IN GOUT //New Day in Medicine 6(38)2021 145-149 https://cutt.ly/mYurl8j

LIST OF REFERENCES:

  1. Yeliseyev M.S. Podagra. V kn.: Revmatologiya. Klinicheskiye rossiyskiye rekomendatsii. Moskva: GEOTAR-Media; 2017.S. 253-64
  2. Klinicheskiye razbory: Vnutrenniye bolezni. Pod red. N.A. Mukhina / M.:Litterra, 2005; s. 237–59.
  3. Klinicheskiye rekomendatsii Rossiyskogo obshchestva urologov po diagnostike i lecheniyu mochekamennoy bolezni / M., 2014; 46 s.
  4. Mazurov V.I., Petrova M.S., Belyayeva I.B. Podagra // «Feniks».Sankt-Peterburg.— 2009.— S. 7–8.
  5. Mezhdunarodnyye rekomendatsii po diagnostike i lecheniyu podagry //Nauchno-prakticheskayarevmatologiya – 2014; 52 (2): 141–6.
  6. Mukhin N.A. Giperurikemiya, arterial’naya giper¬tenziya i khronicheskaya bolezn’ pochek: interpreta¬tsiya vzaimosvyazi i strategiya deystviy / N.A. Mukhin // Klinicheskaya nefrologiya. – 2010. – №4. – S. 4-11
  7. Revmatologiya. Natsional’noye rukovodstvo. Pod red. Ye.L. Nasonova,V.A. Nasonovoy / M.: GEOTAR-Media, 2008; s. 372–80.
  8. Rukovodstvo Yevropeyskoy urologicheskoy assotsiatsii po lecheniyu urolitiaza (EAU), 2013 (sokr.) // Pochki. – 2013; 4: 44–54.
  9. Smirnov A.V., Dobronravov V.A., Rumyantsev A.SH. i dr. Ostroye povrezhdeniye pochek / M.: OOO Izdatel’stvo «Meditsinskoye informatsionnoye agentstvo», 2015; s. 74–6.
  10. Federal’nyye klinicheskiye rekomendatsii. Podagra / M., 2014; 8 s.
  11. Khripunova I.G. Gout. Gouty arthritis / I.G. Khripunova, N.V. Zhurbina // Methodical recommendations. – Stavropol, Ed. SGMA. – 2003. – S. 31
  12. Kodirova Sh.A., Akhmedova N.A., Khodzhanova Sh.I. Gout tibbiyot oliy talim moassasalari professor-kituvchilari, davolash wa tibbiy-pedagogy faculty 5th year talabalari uchun uv-usubiy yllanma Toshkent. 2019 RIOTMA 49 Bet 10-13.21-22.b.
  13. Cirillo P. Uric acid, the metabolic syndrome, and renal disease / P. Cirillo [et al.] // J. Am. Soc. Nephrol. – 2006. – V. 17. – Р. S165-S168
  14. Daudon M. Epidemiology of nephrolithiasis in France. Ann Urol (Paris) 2005; 39 (6): 209–31
  15. Heinig M. Role of uric acid in hypertension, renal disease, and metabolic syndrome / M. Heinig, R.J. Johnson // Cleveland Clinic. Journal of Medicine. – 2006. – V. 73. – P. 1059-1064
  16. Ito H, Kotake K, Nomura K, Masai M. Clinical and biochemical features of uric acid nephrolithiasis. EurUrol 1995; 27(4): 324–8.
  17. Kanellis J. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2 / J. Kanellis [et al.] // Hypertension. – 2003. – V. 41. – Р. 1287-1293
  18. Li CC, Chien TM, Wu WJ. Uric acid stones increase the risk of chronic kidney disease. Urolithyasis 2018; 46 (6): 543–6.
  19. Moon K.W. Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia / K.W. Moon [et al.] // Rheumatology. – 2011. – V. 50(12). – P. 2278-2282 nction from bedside to bench. HypertensRes 2018; 41 (11): 923–31.29.
  20. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR

file

download